Rajan Arathi, Nair Anuja S, Pillai Vinod Soman, Kumar Binod, Pai Anupama R, Benny Bimitha, Veettil Mohanan Valiya
Department of General Virology, Institute of Advanced Virology (IAV), Kerala, 695317, India.
Department of Antiviral Research, Institute of Advanced Virology (IAV), Kerala, 695317, India.
Heliyon. 2024 May 24;10(11):e31905. doi: 10.1016/j.heliyon.2024.e31905. eCollection 2024 Jun 15.
Biocontainment regulations restrict the research on NiV to BSL-4 laboratories, thus limiting the mechanistic studies related to viral entry and allied pathogenesis. Understanding the precise process of viral-particle production and host cell entry is critical for designing targeted therapies or particle-based vaccines. In this study, we have synthesized HiBiT-tagged-NiV-VLPs to ease BSL-2 particle handling. We propose a simple yet effective approach of generating substantial amount of HiBiT-tagged NiV-VLPs by co-expressing viral structural proteins in HEK293T cells. Though homologous to parent virus, the incapacitated replication potential facilitates a BSL-2 handling of these particles. The inclusion of a highly sensitive HiBiT tag on these VLPs allows for a quick detection of viral binding and entry, as well as in assessing the efficiency of neutralizing antibodies using the NanoBiT technology. The HiBiT-tag binds in high affinity with LgBiT (Large BiT an 18 kDa fusion protein and complementary subunit of HiBiT peptide), and the resultant complex elicits high intensity luminescence in the presence of substrate. The VLPs produced were morphologically and functionally identical to the native virus, and the HiBiT-tag permitted their quick application in viral binding, entry, and antibody neutralization assays. "Thus, we report a simple setting for generating HiBiT-NiV VLPs which can be utilized in a BSL-2 laboratory, to concurrently quantify features of NiV assembly, binding and entry. This also offers an alternate-safe and effective platform for viral based antibody neutralization assays
生物安全防护规定将尼帕病毒的研究限制在生物安全四级实验室,从而限制了与病毒进入及相关发病机制有关的机理研究。了解病毒颗粒产生和宿主细胞进入的确切过程对于设计靶向治疗或基于颗粒的疫苗至关重要。在本研究中,我们合成了带有HiBiT标签的尼帕病毒病毒样颗粒,以简化生物安全二级实验室对颗粒的处理。我们提出了一种简单而有效的方法,即通过在人胚肾293T细胞中共表达病毒结构蛋白来大量生成带有HiBiT标签的尼帕病毒病毒样颗粒。尽管这些病毒样颗粒与亲本病毒同源,但无复制能力便于在生物安全二级实验室处理这些颗粒。在这些病毒样颗粒上加入高度敏感的HiBiT标签,可快速检测病毒结合和进入情况,以及使用纳米BiT技术评估中和抗体的效率。HiBiT标签与LgBiT(一种18 kDa融合蛋白,是HiBiT肽的互补亚基)具有高亲和力结合,并且在有底物存在时,形成的复合物会发出高强度荧光。所产生的病毒样颗粒在形态和功能上与天然病毒相同,并且HiBiT标签使其能够快速应用于病毒结合、进入和抗体中和试验。“因此,我们报告了一种简单的方法来生成可在生物安全二级实验室使用的带有HiBiT标签的尼帕病毒病毒样颗粒,以同时量化尼帕病毒组装、结合和进入的特征。这也为基于病毒的抗体中和试验提供了一个安全有效的替代平台。